{"preliminary_commentary":{"by_channel":{"x_thread":33,"youtube":20,"podcast":9,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05411081\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PAPMET2","nct_id":"NCT05411081","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=papmet2-nct05411081. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive cabozantinib S-malate PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and blood and urine sample collection throughout the trial. Patients may also undergo bone scan throughout the trial.","label":"Arm I (cabozantinib S-malate)","type":"ACTIVE_COMPARATOR"},{"description":"Patients receive cabozantinib S-malate PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan or MRI and blood and urine sample collection throughout the trial. Patients may also undergo bone scan throughout the trial.","label":"Arm II (cabozantinib S-malate, atezolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-07-01","type":"ESTIMATED"},"conditions":["Metastatic Papillary Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG 7446","RG-7446","RG7446","RO 5541267","RO-5541267","RO5541267","Tecentriq"],"type":"BIOLOGICAL"},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection"],"type":"PROCEDURE"},{"name":"Bone Scan","otherNames":["Bone Scintigraphy"],"type":"PROCEDURE"},{"name":"Cabozantinib S-malate","otherNames":["BMS-907351","Cabometyx","Cometriq","XL 184","XL-184","XL184"],"type":"DRUG"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography"],"type":"PROCEDURE"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI"],"type":"PROCEDURE"}],"last_update":"2026-10-01","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II Randomized Trial of Cabozantinib (NSC #761968) With or Without Atezolizumab (NSC #783608) in Patients With Advanced Papillary Renal Cell Carcinoma (PAPMET2)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-07-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival","timeFrame":"From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years"}],"references":[],"start_date":{"date":"2023-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial","url":"https://clinicaltrials.gov/study/NCT05411081"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/papmet2-nct05411081"}